These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6785974)

  • 1. Haemostatic function changes in a trial on the secondary prevention of myocardial infarction with sulphinpyrazone.
    Cortellaro M; Boschetti C; Fassio G; Baroni L; Polli EE
    Acta Haematol; 1981; 65(3):193-204. PubMed ID: 6785974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo platelet hyperactivity and factor VIII related antigen increase long after myocardial infarction. A controlled effect of sulfinpyrazone.
    Cortellaro M; Boschetti C; Beggi P; Polli EE
    Scand J Haematol; 1981 Feb; 26(2):106-14. PubMed ID: 6454960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled ex-vivo effect of sulfinpyrazone on platelet function of myocardial infarction patients.
    Cortellaro M; Fassio G; Boschetti C; Basagni M; Polli EE
    Haematologica; 1979 Apr; 64(2):173-89. PubMed ID: 112008
    [No Abstract]   [Full Text] [Related]  

  • 4. A serial study of platelet reactivity throughout the first six months after myocardial infarction: its modification by sulphinpyrazone.
    Kubik MM; Richardson SG
    Postgrad Med J; 1987 May; 63(739):351-6. PubMed ID: 3118351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulphinpyrazone in post-myocardial infarction. Report from the Anturan Reinfarction Italian Study.
    Lancet; 1982 Jan; 1(8266):237-42. PubMed ID: 6120272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting.
    Hertfelder HJ; Bös M; Weber D; Winkler K; Hanfland P; Preusse CJ
    Semin Thromb Hemost; 2005; 31(4):426-40. PubMed ID: 16149021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulfinpyrazone decreases epinephrine-induced platelet aggregation after myocardial infarction.
    Latour JG; Theroux P; Bourassa MG
    Am J Cardiol; 1982 Nov; 50(5):938-44. PubMed ID: 6753559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decrease in renal function due to sulphinpyrazone treatment early after myocardial infarction.
    Lijnen P; Boelaert J; van Eeghem P; Daneels R; Schurgers M; de Jaegere P; van der Stichele E; Vincke J; Fagard R; Verschueren LJ; Amery A
    Clin Nephrol; 1983 Mar; 19(3):143-6. PubMed ID: 6340878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulfinpyrazone in the prevention of cardiac death after myocardial infarction. The Anturane Reinfarction Trial.
    Anturane Reinfarction Trial Research Group
    N Engl J Med; 1978 Feb; 298(6):289-95. PubMed ID: 340942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulphinpyrazone in acute myocardial infarction: studies on cardiac rhythm and renal function.
    Wilcox RG; Richardson D; Hampton JR; Mitchell JR; Banks DC
    Br Med J; 1980 Aug; 281(6239):531-4. PubMed ID: 7000264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A controlled study of the effect of sulfinpyrazone on platelet survival and on platelet-bound 14C-serotonin release in patients with previous myocardial infarction.
    Cortellaro M; Boschetti C; Fassio G; Basagni M; Polli EE
    Acta Haematol; 1979; 61(2):68-74. PubMed ID: 217218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary prevention of myocardial infarction.
    Davies JA
    Int J Clin Pharmacol Res; 1985; 5(5):303-7. PubMed ID: 3905632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulphinpyrazone and the platelet serotoninergic mechanism in ischaemic heart disease.
    Puri VK; Rawat A; Sharma A; Mehrotra A; Hasan M; Shanker K; Verma M; Sinha JN; Bhargava KP
    Br Med J (Clin Res Ed); 1986 Sep; 293(6547):591-3. PubMed ID: 3092937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The effect of sulfinpyrazone on the coagulation-inhibiting action of acenocoumarol].
    Michot F; Holt NF; Fontanilles F
    Schweiz Med Wochenschr; 1981 Feb; 111(8):255-60. PubMed ID: 7015495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulphinpyrazone (Anturan) after myocardial infarction.
    Nicholson MR; Whitlock RM
    N Z Med J; 1979 Sep; 90(644):263. PubMed ID: 390442
    [No Abstract]   [Full Text] [Related]  

  • 16. Antiplatelet agents: rationale and results.
    Kelton JG
    Clin Haematol; 1983 Feb; 12(1):311-54. PubMed ID: 6132693
    [No Abstract]   [Full Text] [Related]  

  • 17. Does sulphinpyrazone prevent recurrence of myocardial infarction?
    Lancet; 1982 Mar; 1(8274):735-6. PubMed ID: 6122022
    [No Abstract]   [Full Text] [Related]  

  • 18. Sulfinpyrazone in the prevention of sudden death after myocardial infarction.
    Anturane Reinfarction Trial Research Group
    N Engl J Med; 1980 Jan; 302(5):250-6. PubMed ID: 6985706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulphinpyrazone (Anturan) after myocardial infarct.
    Watt M
    N Z Med J; 1979 Oct; 90(646):352. PubMed ID: 392352
    [No Abstract]   [Full Text] [Related]  

  • 20. Sulphinpyrazone and renal function following myocardial infarction.
    Choudhury SL; Taylor SH; Wieringa G; Swaminathan R; Morgan DB
    Eur J Clin Pharmacol; 1983; 24(6):747-50. PubMed ID: 6884411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.